# EDGAR Filing Document

**Accession Number:** 0001380585
**File Stem:** 0000921895-26-001662
**Filing Date:** 2026-6
**Character Count:** 8673
**Document Hash:** 0d8bbbb015e9854b4de9b65b0d8e97c6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000921895-26-001662.hdr.sgml**: 20260624

**ACCESSION NUMBER**: 0000921895-26-001662

**CONFORMED SUBMISSION TYPE**: DFAN14A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260624

**DATE AS OF CHANGE**: 20260624

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Seer, Inc.
- **CENTRAL INDEX KEY:** 0001726445
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 821153150
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DFAN14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39747
- **FILM NUMBER:** 261115804

**BUSINESS ADDRESS:**
- **STREET 1:** 3800 BRIDGE PARKWAY, SUITE 102
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94065
- **BUSINESS PHONE:** 650-453-0000

**MAIL ADDRESS:**
- **STREET 1:** 3800 BRIDGE PARKWAY, SUITE 102
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94065

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Seer Biosciences, Inc.
- **DATE OF NAME CHANGE:** 20171226
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Radoff Bradley Louis
- **CENTRAL INDEX KEY:** 0001380585

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** DFAN14A

**MAIL ADDRESS:**
- **STREET 1:** 2727 KIRBY DRIVE
- **STREET 2:** UNIT 29L
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77098

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 14A**

(Rule 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

(Amendment No.)

Filed by the Registrant ☐

Filed by a Party other than the Registrant ☒

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐ Definitive Proxy Statement

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;☒ Definitive Additional Materials

☐ Soliciting Material Under § 240.14a-12

---

| |
|:---|
| SEER, INC. |
| (Name of Registrant as Specified In Its Charter) |
| BRADLEY L. RADOFF<br> THE RADOFF FAMILY FOUNDATION<br> JEC II ASSOCIATES, LLC<br> THE MOS TRUST<br> MOS PTC, LLC<br> MICHAEL TOROK<br> HOWARD H. BERMAN<br> JOSHUA S. HOROWITZ<br> LUIS E. RINALDINI |
| (Name of Persons(s) Filing Proxy Statement, if other than the Registrant) |

---

Payment of Filing Fee (Check all boxes that apply):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;☒ No fee required

☐ Fee paid previously with preliminary materials

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

Bradley L. Radoff, Michael Torok and the other participants named herein (collectively, the "Radoff-JEC Group") have filed a definitive proxy statement and accompanying **WHITE** universal proxy card with the Securities and Exchange Commission to be used to solicit votes for the election of its slate of highly qualified director nominees at the 2026 annual meeting of stockholders of Seer, Inc., a Delaware corporation (the "Company").

On June 24, 2026, the Radoff-JEC Group issued the following press release:

**The Radoff-JEC Group Urges Seer, Inc. Stockholders to Vote for Boardroom Change Today**

*Believes New Independent Directors Are Needed to Correct the Board's Misaligned Priorities and Prevent Further Value Destruction*

 

*Reveals Seer's Board Has Not Responded to the Radoff-JEC Group's Stockholder-Friendly Offer Made on June 15 to Resolve the Ongoing Proxy Contest, Demonstrating the Board's Focus on its Own Entrenchment*

![](image_002.jpg)

HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the "Radoff-JEC Group" or "we"), who collectively own approximately 7.7% of the outstanding shares of Seer, Inc. (NASDAQ: SEER) ("Seer" or the "Company"), today issued the following statement.

&nbsp;&nbsp;&nbsp;&nbsp;· **Seer's Board of Directors (the "Board") has destroyed value for stockholders while enriching Company insiders:** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o The Company has posted a -97.0% share price decline since its December 2020 IPO. <sup>1</sup>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o Seer has generated cumulative reported losses exceeding $465 million since its IPO. <sup>2</sup>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o Seer has delivered virtually no revenue growth over the last three fiscal years, while investing over
$160 million. <sup>3</sup>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o The Board has rewarded Chairman and CEO Omid Farokhzad, M.D. with nearly $37 million in cumulative compensation
while a stockholder who purchased one share at the time of the IPO ($19.00) would be left with less than $0.63. <sup>4</sup>

&nbsp;&nbsp;&nbsp;&nbsp;· **Seer has no plan to create stockholder value under Chairman and CEO Omid Farokhzad, M.D.:** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o Dr. Farokhzad has destroyed more than $1 billion in investor capital across five separate companies, evidence
supporting our belief that he is incapable of turning around Seer. <sup>5</sup>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o The strategic plan overseen by the Board anticipates Seer will not achieve profitability until 2031. <sup>6</sup>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o The Board rejected our three proposals to acquire Seer for premiums of 33% - 42% to its unaffected share
price and a contingent value right – proposals which we believe provide substantially greater certainty of value creation than the
Company's current strategic plan – without even engaging with us.

&nbsp;&nbsp;&nbsp;&nbsp;· **Seer's Board has not responded to our proposal to settle this proxy contest:** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o On June 15, 2026, we proposed to end our ongoing proxy contest in exchange for Seer adopting governance
enhancements and conducting a tender offer for 20 million shares at $2.50 per share, which would be in line with the Board's authorized
buyback program and management's statements that there is a "significant dislocation" in the Company's share price. <sup>7</sup>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o More than a week later, the Board has still not responded to our settlement offer – which it requested
in the first place – demonstrating that its priority is not delivering value or governance improvements for stockholders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o Instead of focusing on opportunities to maximize value for stockholders as Seer's share price has
consistently traded at a significant discount to net cash, the Board has diluted stockholders by repeatedly issuing large grants of restricted
stock units and in-the-money options to Dr. Farokhzad and President and CFO David Horn.

**Vote <u>FOR</u> the Radoff-JEC Group's Nominees – Howard H. Berman, Ph.D., Joshua S. Horowitz and Luis E. Rinaldini – Today to Prevent Further Value Destruction**

**Do <u>NOT</u> Vote for Omid Farokhzad, M.D., Terrance McGuire or Dipchand (Deep) Nishar**

Questions about how to vote? Contact (888) 368-0379 or info@saratogaproxy.com.

Visit www.SaratogaProxy.com/SEER to learn more.

------

<sup>1</sup> FactSet. Share price decline from December 4, 2020 through April 10, 2026, the trading day immediately prior to the Radoff-JEC Group's submission of its initial proposal to acquire the Company.

<sup>2</sup> The Company's Form 10-K for the year ended December 31, 2025 filed on March 2, 2026.

<sup>3</sup> Company Form 10-K filings.

<sup>4</sup> Company proxy statements. FactSet; share price decline from December 4, 2020 through December 31, 2025.

<sup>5</sup> Seer, BIND Therapeutics, Inc., Selecta Biosciences, Inc., Tarveda Therapeutics, Inc. and Senti Biosciences Holdings, Inc.

<sup>6</sup> Company PRE 14A filed on October 10, 2025.

<sup>7</sup> On the Company's Q1 2026 earnings call held on May 13, 2026, President and CFO David Horn said: "Our opportunistic share repurchase in the quarter reflect our continued belief that there is a significant dislocation in our share price."

**Contacts**

Greg Lempel

greg@fondrenlp.com

or

Saratoga Proxy Consulting LLC

John Ferguson / Joseph Mills, 212-257-1311

info@saratogaproxy.com